EP
UTHR icon

Eversept Partners’s United Therapeutics UTHR Stock Holding History

Eversept Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,600
Closed -$1.64M – 106
2021
Q4 		$1.64M Buy
+7,600
New +$1.49M 0.1% 83

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Eversept Partners's UTHR Position: Q2 2026 in Review

Eversept Partners increased its United Therapeutics (UTHR) stake by 8.9% in Q2 2026, buying an estimated $13.2M and bringing the position to 287,668 shares worth $156M. The position accounts for 8.09% of the portfolio, ranked #1.

Eversept Partners first reported a position in UTHR in Q2 2020 and has held it in 25 quarters since. The position peaked at $157M in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Eversept Partners held 287,668 shares of United Therapeutics worth $156M as of Q2 2026.
  • Eversept Partners bought 23,397 United Therapeutics shares in Q2 2026, an estimated $13.2M.
  • United Therapeutics made up 8.09% of Eversept Partners's portfolio in Q2 2026, its #1 holding.
  • Eversept Partners first reported a position in United Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Eversept Partners's United Therapeutics position peaked at $157M in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.